Natural killer (NK) cell alloreactivity has been implicated in graftversus-host (GVH) and GVL immunity. Though the basic mechanisms of NK cell alloreactivity are well described, comparatively little is known about its clinical effects. NK cells contribute to immunity against malignant and virally infected cells through their ability to recognize and directly kill host cells that have downregulated MHC-I. There is no Ag specificity or requirement for prior sensitization. Instead, cytotoxicity towards a particular target cell is regulated by a balance of activating and inhibitory cell-cell contacts. 1 An important and proximal factor in this regulation is the inhibitory signal created when inhibitory killer Ig-like receptors (KIR) on NK cells engage MHC-I molecules on target cells. 2 Conversely, the absence of HLA class I on a target cell allows other activating signals to dominate, and leaves the target vulnerable to lysis.
Distinct inhibitory KIR have binding specificity for MHC-I molecules encoded by specific HLA class I alleles. Although KIR and HLA class I are encoded on separate chromosomes, a licensing process that is thought to occur during NK cell maturation in the BM protects against the circulation of autoreactive cytotoxic NK cells. 3 Applied to the scenario of allogeneic hematopoietic SCT, certain mismatches at HLA-B and HLA-C loci would be expected to result in circulation of donor-derived NK cells bearing KIR with no compatible ligand on recipient cells, creating the potential for NK cell-mediated alloreactivity in the GVH direction. Such KIR ligand incompatibility can predict the presence of alloreactive NK cells in transplant recipients. 4 This has led to the hypothesis that KIR ligand incompatibility might impart a protective NK cell-mediated GVL effect. Supporting this hypothesis, KIR ligand incompatibility was associated with a dramatic reduction in relapse or death (10-year relative risk reduction of 52%) in a cohort of 112 patients who received T-celldepleted haploidentical transplants for high-risk AML. 4, 5 Other studies stratifying patients who received BM or PBSC transplants variably reported increased, decreased or unchanged relapse rates and OS associated with predicted NK cell alloreactivity. 6 The patients in these studies differed significantly with regard to their transplantation protocols, degree of T-cell depletion, methods for predicting NK cell alloreactivity, and the underlying malignancies.
NK-cell effects may be more pronounced in umbilical cord blood transplantation (UCBT) compared with other transplant modalities. Donor cord units are typically chosen based on Ag, rather than allele-level typing and with higher tolerance for mismatch, and HLA-C, an important determinant of KIR ligand compatibility, is not usually considered. In addition, when UCBT is compared with peripheral stem cell transplantation from matched unrelated donors, NK-cells engraft earlier and more robustly, and T-cell engraftment is delayed. 7 Therefore, UCBT may represent a setting in which, like haploidentical transplantation, KIR ligand incompatibility might be associated with protection from relapse.
Two prior studies have examined KIR ligand incompatibility in patients undergoing umbilical cord blood (UCB) transplantation.
The first examined 218 patients from the multi-institutional Eurocord registry who underwent single-unit UCB transplantation for AML (n ¼ 94) or ALL (n ¼ 124) and found that KIR ligand incompatibility in the GVH direction was associated with reduced relapse (20% vs 37%, P ¼ 0.03) and increased OS (57% vs 40%, P ¼ 0.02) after a median follow-up time of 14 months; 8 these differences persisted upon re-analysis after 34 months. 9 AML patients seemed to have benefited disproportionately from incompatibility. Most patients received myeloablative conditioning. The second study described 257 recipients of single or double UCBT (DUCBT) transplantation at the University of Minnesota, about half of whom received reduced-intensity conditioning (RIC). 10 KIR ligand incompatibility was not associated with any difference in outcome among patients who received myeloablative conditioning, but among patients who received RIC, incompatibility was associated with higher rates of acute GVHD and decreased OS. It therefore remains unresolved whether or in what circumstances KIR ligand incompatibility affects clinical outcomes in UCBT.
We examined outcomes in a single-institution cohort of 80 patients who underwent DUCBT between December 2003 and July 2010, stratified according KIR ligand incompatibility in the GVH direction. KIR ligands were determined to be incompatible in 35/80 patients based on the presence in at least one donor cord of a ligand for one of the predominant inhibitory KIR when no ligand for that KIR was present in the recipient. 11 Patients underwent DUCBT after either RIC consisting of fludarabine, melphalan and anti-thymocyte globulin (one patient received fludarabine and BU) (N ¼ 59), or fully myeloablative conditioning with fludarabine, CY and TBI (N ¼ 21) (Table 1) . GVHD prophylaxis was with either cyclosporine or tacrolimus with mycophenolate mofetil (N ¼ 26) or with tacrolimus and sirolimus (N ¼ 54). The median age was 48 years. Forty-nine percentage of patients had myeloid malignancies, and HLA match was similar between KIR ligandcompatible and -incompatible groups. The median degree of HLA mismatch, defined as the number of mismatched alleles at HLA-A, -B, -C and -DR between the patient and each cord, was 5 (range 2-6) for KIR ligand compatible and 6 (range 4-7) for KIR incompatible patients. The median follow-up time among the survivors for the entire cohort was 34 months and did not differ between the two groups (P ¼ 0.9). All patients have been previously reported 12, 13 and previously gave consent for inclusion in retrospective data analysis.
Associations between categorical variables were assessed by w 2 -test and Fisher's exact test. The Wilcoxon rank-sum test was performed to test differences between continuous variables. All P-values are two-sided. Kaplan-Meier curves for OS and PFS were constructed for each group and compared with the log-rank test. Cumulative incidence curves for relapse and non-relapse mortality (NRM) were constructed, reflecting NRM and relapse as competing risks. The difference between cumulative incidence curves in the presence of a competing risk was tested using the Gray method. Cumulative incidence curve for GVHD was constructed, reflecting relapse or death without developing GVHD as a competing risk.
The median time to engraftment of neutrophils (21 days in both groups, P ¼ 0.3) and platelets (42 days in both groups, P ¼ 0.95) did not differ between the groups receiving transplants from KIR ligand-compatible or -incompatible donors. The cumulative incidence of acute GVHD (grade X2) was similar between the two groups (22% vs 17%, P ¼ 0.52). The cumulative incidence of chronic GVHD was also similar between the two groups (2-year cumulative incidence 19% vs 24%, P ¼ 0.4). Graft rejection, defined as donor-predominant engraftment followed by loss of donor chimerism, occurred in five patients in the KIR ligand-incompatible group and one patient in the KIR ligand-compatible group (P ¼ 0.08). Among the patients with graft rejection in the KIR ligand-incompatible group, 4/5 exhibited cord-vs-cord, and 3/5 exhibited host-versus-graft, KIR ligand incompatibility.
There was no significant difference in the cumulative incidence of relapse between the groups receiving KIR ligand-compatible and -incompatible transplants (3-year cumulative incidence: 40% vs 44%, P ¼ 0.67). KIR ligand incompatibility was also not associated with PFS (3-year PFS: 29% vs 24%, P ¼ 0.44) or OS (3-year OS: 40% vs. 34%, P ¼ 0.45). OS, PFS and relapse were separately analyzed for the subsets of the cohort with myeloid diagnoses. There were no differences in OS, PFS or relapse based on KIR ligand incompatibility in these subsets. A separate analysis was also conducted on the subsets receiving myeloablative and RIC; there were no differences in OS or PFS.
In summary, we did not observe any significant associations in our cohort between receipt of UCB units with incompatible KIR ligands in the GVH direction and clinical outcomes. Our cohort was relatively small and was heterogeneous with respect to the range of underlying diagnoses and conditioning regimen. This limited our ability to detect differences among subgroups that may have unique sensitivities to KIR ligand compatibility. Contrasting our cohort to the two other cohorts in which this association has been previously examined, [8] [9] [10] ours exclusively contains recipients of double-unit transplants, and our RIC regimen was significantly more myeloablative than the RIC regimen used in the Minnesota cohort. We did not in our study conduct KIR genotyping on donor units or conduct functional studies for the presence of recipient-reactive donor NK cells. In light of recent data indicating the importance of activating KIR 14 and KIR polymorphisms, 15 our simple algorithm focusing on ligands for inhibitory KIR is likely insufficient for the purposes of predicting clinically relevant NK cell alloreactivity. Our results do not support the use of such a model in donor selection for DUCBT.
